Long-term follow-up after combined fissurectomy and Botox injection for chronic anal fissures by Scholz, Th et al.
ORIGINAL ARTICLE
Long-term follow-up after combined fissurectomy and Botox
injection for chronic anal fissures
Th. Scholz & F. H. Hetzer & D. Dindo & N. Demartines &
P. A. Clavien & D. Hahnloser
Accepted: 22 December 2006 / Published online: 30 January 2007
# Springer-Verlag 2007
Abstract
Background and aims Chronic anal fissures are difficult to
treat. The aim of this retrospective study was to determine
the outcome of combined fissurectomy and injection of
botulinum toxin Type A (BT).
Materials and methods Between January 2001 and August
2004, 40 patients (21 women), median age 37 years (range
18 to 57), underwent fissurectomy and BT injection.
Fissurectomy was performed followed by injection of
10 U of BT into the internal anal sphincter on both sides
of the fissure. All patients were clinically checked 6 weeks
after the operation. At 1 year, patients were sent a detailed
questionnaire regarding symptoms, recurrence and further
treatment for evaluation of long-term results.
Results/findings At 6 weeks, 38 patients (95%) were free of
symptoms. No adverse effects were detected. The response
rate of questionnaires was 93%; the median follow-up was
1 year (range 0.9 to 1.6). In the long-term, a recurrence was
found in four patients. These patients were treated
successfully with repeated fissurectomy and BT injections
and salvage procedures, respectively. Overall, the success
rate of combined fissurectomy and BT injection was 79%.
Interpretation/conclusion Combined fissurectomy and
Botox injection for chronic anal fissure is an excellent and
safe procedure with low morbidity and a high healing rate.
Keywords Chronic anal fissure . Fissurectomy .
Botulinum toxin type A . Long-term results
Introduction
The treatment of chronic anal fissures is still challenging.
Whereas an acute fissure usually responds to conservative
treatment in up to 90%, chronic anal fissures are mainly
refractory to non-surgical strategies with low healing rates
of 30–40% [1]. Therefore, surgery is often mandatory in
chronic fissures [2]. Since the first description by Notaras
[3], lateral internal sphincterotomy (LIS) has become the
treatment of choice for chronic anal fissures with a high
healing rate of about 95% [4]. However, LIS constantly
showed a risk of incontinence to flatus in up to 45% [5–8]
and for stool incontinence in up to 22% [9], respectively.
A high anal resting pressure leads to an impairment of
anal blood supply and, thus, is considered to be a causative
factor for the development of anal fissures. After 6–8 weeks,
healing of the acute anal fissure is unlikely and should be
considered chronic [10, 11]. Besides a high resting anal
pressure, the healing of chronic fissures is compromised by
a sentinel skin tag and a hypertrophied anal papilla, which
are very often inherent with chronic fissures [12].
Due to recent studies reporting faecal incontinence
several years after LIS [7, 13–15], the medical reduction
of the sphincter spasm by Botulinum toxin Type A (BT) is
an alternative to surgery [16]. This exotoxin produces a
constant reduction in maximum resting pressure for 2–
3 months by binding to the presynaptic nerve terminal at
the neuromuscular junction, thus, preventing the reuptake
of acetylcholine [11, 17]. This chemical sphincterotomy is
able to achieve healing rates up to 80% [18] and is,
therefore, less favorable compared to LIS, while continence
is not significantly affected [16, 19].
To increase healing rates of chronic anal fissures Gupta
and Kalaskar [20] suggested to remove any sentinal skin
tag and hypertrophied anal papilla during sphincterotomy,
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as these mechanical factors may compromise wound
healing.
As high anal resting pressures as well as mechanical
factors play an eminent role in the development of chronic
anal fissures, reduction of the anal tone in combination with
fissurectomy might be a promising novel approach. We
hypothesize that fissure debridement is a keystone in the
treatment of chronic anal fissures and combined it with BT
injection. This new approach to chronic anal fissures has
recently been documented with a complete healing rate of
93% by Lindsey et al. [19], but follow-up of these patients
was limited to 16 weeks. Recurrences of surgically and
medically treated chronic anal fissures can often develop
beyond this time frame [13]. Therefore, we, here, present
our long-term outcome of fissure debridement and BT
injection together with patient’s satisfaction.
Materials and methods
From January 2001 to August 2004, 40 consecutive
patients with chronic anal fissures treated with fissurectomy
combined with BT were enrolled in the study. Inclusion
criteria were patients older than 16 years of age with
persistent signs and symptoms of chronic anal fissures that
lasted more than 6 weeks. Morphological signs of chronic
anal fissures were defined as present fibrosis, induration of
fissure edges and visible muscle fibres. Exclusion criteria
were determined as acute fissure (<6 weeks), atypical
fissure (multiple, irregular, off the midline), chronic fistulas
in ano, coexsistence of inflammatory bowel disease, anal
abscess, malignant disease, as well as post-obstetric and
neutropenia-associated fissures.
After informed consent, fissurectomy was performed
under general or regional anaesthesia. After examination of
the fissure, the fibrotic edges were excised with a scalpel
until a normal non-fibrotic anodermal tissue showing
sufficient bleeding was reached. Then, a triangle was
created at the distal edge of the fissure allowing wound
drainage. If present, the sentinel skin tag was excised. The
granulation tissue at the base of the fissure was curetted
until there were clean muscle fibres of the internal anal
sphincter. There was no use of diathermy, and careful
attention was given not to damage the internal anal
sphincter. Once fissurectomy was completed, 10 U of BT
(Allergan, Lachen, Switzerland) were injected on each side
of the fissure into the internal anal sphincter (10 U BT were
dissolved in 2 ml of 0.9% natrium chloride solution). The
injection site was adjacent to the location of the fissure.
Patients were treated with stool regulation using Macro-
golum 3350 (Transipeg®; Mundipharma Medical, Basel,
Switzerland) and topical lidocaine as anaesthetic agent for
6 weeks.
Six weeks after the operation, patients were re-evaluated
in our outpatient clinic. Improvement of fissure healing and
symptoms relief at 6 weeks were graded in four different
stages as described by Lindsey et al. [10]:
I. Fissure healed/symptoms resolved/no surgery required
II. Fissure unhealed/symptoms resolved/no surgery
required
III. Fissure unhealed/symptoms satisfactorily improved/no
surgery required
IV. Fissure unhealed/symptoms not satisfactorily im-
proved/surgery required
Incontinence was documented according to the Wexner
score [9]. Fissure healing was defined as completely
resolved symptoms according to stages I and II as described
above.
One year after surgery, all patients were sent a detailed
questionnaire regarding symptoms and patients’ satisfac-
tion. The two classical symptoms of chronic anal fissures
(postdefecatory pain and bleeding) were compared with
baseline parameters preoperatively. Overall satisfaction of
patients concerning the treatment was evaluated using the
visual analogue scale. Related to the questionnaire, healing
was again defined as completely resolved symptoms.
Differences of symptoms within the study group were
statistically analysed for paired data and a dichotomous
endpoint using the Mc Nemar test. A p<0.05 was
considered significant. Data are presented as median
(range).
Results
Patient demographics
Forty patients (21 women) with a median age of 37 years
(range 18–57 years) were treated with fissurectomy
combined with BT injection. Thirty-four (85%) fissures
were posterior, and six were located at the anterior portion.
A sentinel skin tag was present in 26 (65%) patients.
During the study period, 152 patients were conservatively
treated for an acute anal fissure in our hospital. Thirty
patients (20%) were not responding to this therapy after
3 months (range 2 to 6 months) and were enrolled into the
study. Twelve patients were primarily seen for chronic anal
fissure with a median duration of symptoms of 16 months
(range 15 to 19 months).
Surgical complications and morbidity
Surgical complications were graded according to a validat-
ed treatment-orientated score [21]. Five patients presented
with a grade I complication (any deviation from the normal
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postoperative course without the need for pharmacological
treatment or surgical, endoscopic and radiological inter-
ventions). One of these patients complained about mild
incontinence 6 weeks after surgery (Wexner score 5).
Incontinence improved by dietary measures and completely
disappeared as evaluated during long-term follow-up. Three
of these patients presented with ongoing anal bleeding that
spontaneously resolved on the first postoperative day. The
fifth patient developed a small abscess that drained and
healed spontaneously. No complications requiring surgical
or pharmacological intervention (grades II to III) were
observed.
Short-term outcome
Six weeks after the operation, all 40 patients were re-
evaluated and interviewed in our outpatient clinic. Ten
patients (25%) had a completely healed fissure and resolved
symptoms (stage I). In 26 patients (65%), the fissure was
still present, but there were no complaints of any symptoms
at all (stage II). Four patients (10%) presented with
persistent symptoms and unhealed fissures (stage IV), of
which, two were successfully treated by a second fissur-
ectomy and BT injection. Therefore, the primary short-term
success concerning fissure healing was 90% (36/40).
Long-term outcome
After a median of 1 year (range 0.9 to 1.6 years), all patients
were sent a detailed questionnaire for evaluation of the long-
term follow up. The response rate was 93% (37/40). Figure 1
shows the reduction of typical fissure symptoms compared
to the preoperative baseline values: Postdefecatory pain
significantly improved by 92% (P<0.01) and bleeding by
100% (P<0.001), respectively.
Four patients who presented with short-term failure after
6 weeks were all without complaints after 1 year. In two
patients, repeated fissurectomy and injection of BT was
successfully performed. The other two patients were treated
conservatively by dietary measures. Another four patients
who showed healing in the 6-week follow-up developed a
recurrence of the fissure requiring further treatment (stage
IV). Overall, total healing rate was 79% according to the
Kaplan–Meier analysis after fissurectomy and BT injection.
Patients’ satisfaction
With the questionnaire, we evaluated the overall satisfac-
tion of our therapy using a visual analogue scale (0 = not at
all–10 = very satisfied) resulting in a median of 9 (range 7
to 10) among all 37 patients.
Discussion
The combination of fissurectomy and BT achieved an
excellent healing rate of 79% after 1 year. The procedure
was safe with low morbidity, and only one reported mild
disturbance in continence in the first weeks postoperatively.
Although LIS demonstrated excellent results regarding
fissure healing and continence due to a significant decline
in resting anal pressure [13], numerous reports revealed a
significant risk for developing disturbances in anal conti-
nence with a reported incontinence to flatus from 6 to 35%
and minor faecal soiling from 8 to 22% in the long-term [2,
5, 14, 22]. Today, it is known that faecal incontinence may
occur many years after sphincter damage such as from
complicated delivery or anal surgery [23]. For that reason,
incontinence after LIS has probably been underestimated [7].
In recent years, there has been a shift towards medical
therapy to overcome these surgical side effects. A deeper
understanding of the physiology of the anal sphincter
allowed medical approaches to influence the sphincter tone
[24]. Since the introduction of BT for chronic anal fissure
in 1994 [25], many studies have been conducted to evaluate
its role and effectiveness. Short-term results of the first
studies have been very promising, with healing rates of 60–
70% [26, 27]. Thereafter, numerous reports described
healing rates with single injection of BT between 40–90%
[1, 10, 16]. However, with meta-analysis, healing rates are
found to be always lower than 80% and, therefore, BT is
still inferior to surgical procedures [11, 18, 28–30]. This is
underlined by De Nardi et al. [1] showing recently that BT
failed in one third of patients after 3 months. In the long-
term, healing rate was only 40% after 46 months.
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Fig. 1 Long-term follow-up of symptoms as determined by
questionnaires
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We believe that BT is effective in the reduction of anal
resting pressure, but many patients with chronic anal fissure
show clear signs of chronicity (indurated fissure edges, scar
tissue, hypertrophied anal papilla and sentinel skin tag) and,
therefore, the concept of BT alone is not able to overcome
these pathophysiological features needed to achieve appro-
priate tissue healing. Fissurectomies with removal of the
fibrotic edges of the fissure and resection of anal papilla
and the skin tag, respectively, have been successfully
applied as alternative for LIS in the treatment of chronic
anal fissures in pediatric studies [31]. The concept of
fissurectomy in combination with reversible chemical
sphincterotomy as used in the present study was first
introduced by Engel et al. [32]. After a 29-month follow-
up, all 17 patients showed a healed anal fissure after
fissurectomy followed by nitroglycerin (GTN) application.
Lindsey et al. [19] reported complete healing rates of 93%
by fissurectomy and injection of BT after 4 months. These
and our data demonstrate that a combined strategy consist-
ing of fissurectomy and chemical sphincterotomy is a
promising approach with low morbidity.
Nitrates such as GTN are effective and inexpensive
drugs for reduction of anal resting pressure. However, side
effects may compromise patient’s compliance, as headache
has been reported to occur in up to 72% [1, 33–35]. Several
manometric studies have demonstrated BT to be as
effective as nitrates with less side effects [25, 26, 36];
although incontinence of flatus and stool incontinence has
been reported in up to 10 and 5%, respectively, dependent
on dosage [18]. However, in our study using 10 U of BT,
mild stool incontinence was only observed in one patient
(2.5%). The main disadvantage of BT is its expensiveness
(100 U Botox® costs 350 euro). Nevertheless, a single drug
injection and low morbidity make BT more favourable to
nitrates. Overall, treatment with GTN, nifedipin, diltiazem
and lidocaine has also been shown to be ineffective [30].
BT causes paralysis of skeletal muscles blocking the
presynaptic release of acetylcholine. Therefore, BT was first
injected into the external sphincter [25]. Recent studies
have demonstrated that BT may also be effective in non-
striated muscle fibres. Jones et al. [36] showed that injection
of BT into the internal anal sphincter reduces the myogenic
tone and contractile response to sympathetic stimulation. In
this study, BT was injected into the internal anal sphincter.
Overall, clear information about dosage, precise injection
site and number of injections is still incomplete.
In addition to BT injection, a fissurectomy, as described
by Gupta et al. [12], was performed in all patients in our
study. The fibrotic edges of the fissure were excised as well
as any sentinel skin tag and hypertrophied anal papilla.
Great emphasis was led on the formation of a drainage
triangle at the distal end of the fissure to allow constant
wound drainage.
In conclusion, fissurectomy and BT injection treats both
main causes of chronicity of anal fissures: the presence of
bradytrophic scar tissue and the high resting anal pressure.
This combined treatment strategy is very promising for the
treatment of chronic anal fissures with a high success rate
and a low morbidity. Further randomized trials comparing
fissurectomy alone versus fissurectomy combined with BT
have to reveal whether fissurectomy alone can be as
effective as combined therapies.
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